Amedeo Smart

Free Medical Literature Service

 

Amedeo

Alzheimer's Disease
  Free Subscription

Articles published in
Ann Neurol
    March 2026
  1. TROPEA TF, Stevenson PA, Flitter M, Meehan D, et al
    Association between Plasma P-tau217 and Alzheimer's Copathology and Cognitive Decline in Parkinson's Disease.
    Ann Neurol. 2026 Mar 18. doi: 10.1002/ana.78201.
    >> Share

  2. XU YR, Tao Y, Lish AM, Li S, et al
    Novel Monoclonal Antibody Detects Small Abeta Oligomers More Sensitively Than Lecanemab in Alzheimer's Disease CSF, Serum and Culture Media.
    Ann Neurol. 2026 Mar 16. doi: 10.1002/ana.78196.
    >> Share

  3. BROWN CA, Cousins KAQ, Korecka M, McGrew E, et al
    Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease Using PET and Plasma Biomarkers.
    Ann Neurol. 2026 Mar 15. doi: 10.1002/ana.78194.
    >> Share

  4. IBANEZ L, Pottier C, Beric A, Western D, et al
    Understanding Neurodegenerative Diseases From the -Omics Perspective: Lessons Learnt.
    Ann Neurol. 2026;99:566-587.
    >> Share

    February 2026
  5. B SZABO A, Curot J, Gerard F, Rulquin F, et al
    Refining Detection of Subclinical Epileptiform Activity in Alzheimer's Disease: A Case-Control Study and Call for a Consensus.
    Ann Neurol. 2026 Feb 11. doi: 10.1002/ana.78135.
    >> Share

    January 2026
  6. CANOVAS R, Cox T, Dore V, Bourgeat P, et al
    When Does Alzheimer's Disease Start? Plasma Abeta42/40 Assays Show Steep Changes at Abeta-PET Centiloid 15, Mean Age of 66 Years.
    Ann Neurol. 2026 Jan 26. doi: 10.1002/ana.78163.
    >> Share

  7. MABOUDIAN SA, Fonseca CS, Martersteck AC, Chao Y, et al
    Tau Pathology in Alzheimer's Disease Uniquely Affects Sulcal Depths.
    Ann Neurol. 2026 Jan 24. doi: 10.1002/ana.78166.
    >> Share

    December 2025
  8. COUSINS KAQ, Boyle R, Morse C, Verma A, et al
    Electronic Health Records to Test Multimorbidity Influences to Plasma Biomarker Interpretation for Alzheimer's Disease.
    Ann Neurol. 2025 Dec 25. doi: 10.1002/ana.78114.
    >> Share

    October 2025
  9. PIURA YD, Satyadev N, Corriveau-Lecavalier N, Kuchenbecker LA, et al
    Decoding the Clinical Features that Associate with Progression, Causes, and Outcomes in Patients with Suspected Rapidly Progressive Dementia.
    Ann Neurol. 2025;98:764-776.
    >> Share

    September 2025
  10. ABDELMOITY O, Wisch JK, Kennedy JT, Goyal M, et al
    Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease.
    Ann Neurol. 2025 Sep 22. doi: 10.1002/ana.78002.
    >> Share

  11. GRAFF-RADFORD J, Syrjanen JA, Vemuri P, Lowe VJ, et al
    Predictive Value of Plasma Biomarkers in Tau-PET Transitions.
    Ann Neurol. 2025 Sep 10. doi: 10.1002/ana.78003.
    >> Share

  12. BUCKLEY RF, Scott M, McGrath ER, Coughlan G, et al
    Midlife Steroid-Binding Globulin Levels and In Vivo Neuroimaging Measures of Tau in Older Men and Women.
    Ann Neurol. 2025;98:524-532.
    >> Share

    July 2025
  13. GUNASEKARAN TI, Sanchez D, Reyes-Dumeyer D, Ventura R, et al
    Frequency of Microvascular Pathology and Hippocampal Atrophy on Magnetic Resonance Imaging in a Community Study of Alzheimer's Disease with Blood-Based Biomarkers.
    Ann Neurol. 2025 Jul 30. doi: 10.1002/ana.70006.
    >> Share

  14. WOOD ALEXANDER M, Fischer DL, VandeVrede L, Nichols E, et al
    Sex Differences in Associations of Lewy Body Disease with Alzheimer's Disease and Cognitive Decline.
    Ann Neurol. 2025 Jul 11. doi: 10.1002/ana.27308.
    >> Share

    June 2025
  15. MILA-ALOMA M, Tosun D, Schindler SE, Hausle I, et al
    Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks.
    Ann Neurol. 2025 Jun 20. doi: 10.1002/ana.27285.
    >> Share

  16. REYES A, Zawar I, Punia V, Sarkis RA, et al
    Clinical and Cognitive Profiles of Individuals with Alzheimer's Disease and Comorbid Seizures.
    Ann Neurol. 2025 Jun 16. doi: 10.1002/ana.27284.
    >> Share

    April 2025
  17. AFFANEH A, Linden AK, Tunc-Ozcan E, Tsai YH, et al
    Inhibition of Bone Morphogenetic Protein Signaling Prevents Tau Pathology in iPSC Derived Neurons and PS19 Mice.
    Ann Neurol. 2025;97:657-672.
    >> Share

    March 2025
  18. LAGARDE J, Maiti P, Schonhaut DR, Blazhenets G, et al
    Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts.
    Ann Neurol. 2025 Mar 17. doi: 10.1002/ana.27233.
    >> Share

  19. ARRIOLA-INFANTE JE, Morcillo-Nieto AO, Zsadanyi SE, Franquesa-Mullerat M, et al
    Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down Syndrome.
    Ann Neurol. 2025 Mar 14. doi: 10.1002/ana.27226.
    >> Share

    February 2025
  20. KEUM M, Byun MS, Yi D, Ahn H, et al
    The Use of Antihypertensive Medication and In Vivo Alzheimer's Disease Pathology.
    Ann Neurol. 2025 Feb 17. doi: 10.1002/ana.27204.
    >> Share

    January 2025
  21. WILLIAMS ME, Fennema-Notestine C, Bell TR, Lin SJ, et al
    Neuroimaging Predictors of Cognitive Resilience against Alzheimer's Disease Pathology.
    Ann Neurol. 2025 Jan 31. doi: 10.1002/ana.27186.
    >> Share

  22. NOGUCHI-SHINOHARA M, Shuta K, Murakami H, Mori Y, et al
    Lecanemab-Associated Amyloid-beta Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's Disease.
    Ann Neurol. 2025 Jan 6. doi: 10.1002/ana.27175.
    >> Share

    October 2024
  23. YUAN J, Tao Q, Ang TFA, Liu C, et al
    The Relationship between Framingham Stroke Risk Profile on Incident Dementia and Alzheimer's Disease: A 40-Year Follow-Up Study Highlighting Female Vulnerability.
    Ann Neurol. 2024 Oct 15. doi: 10.1002/ana.27108.
    >> Share

    September 2024
  24. ABDELNOUR C, Young CB, Shahid-Besanti M, Smith A, et al
    Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease.
    Ann Neurol. 2024;96:526-538.
    >> Share

  25. CHEN C, Lan Z, Tang X, Chen W, et al
    Human-Derived Induced GABAergic Progenitor Cells Improve Cognitive Function in Mice and Inhibit Astrocyte Activation with Anti-Inflammatory Exosomes.
    Ann Neurol. 2024;96:488-507.
    >> Share

    August 2024
  26. MASURKAR AV, Marsh K, Morgan B, Leitner D, et al
    Factors Affecting Resilience and Prevention of Alzheimer's Disease and Related Dementias.
    Ann Neurol. 2024 Aug 17. doi: 10.1002/ana.27055.
    >> Share

    July 2024
  27. BRIER MR, Schindler SE, Salter A, Perantie D, et al
    Unexpected Low Rate of Amyloid-beta Pathology in Multiple Sclerosis Patients.
    Ann Neurol. 2024 Jul 4. doi: 10.1002/ana.27027.
    >> Share

    June 2024
  28. LAH JJ, Tian G, Risk BB, Hanfelt JJ, et al
    Lower Prevalence of Asymptomatic Alzheimer's Disease Among Healthy African Americans.
    Ann Neurol. 2024 Jun 25. doi: 10.1002/ana.26960.
    >> Share

  29. SOLEIMANI-MEIGOONI DN, Smith R, Provost K, Lesman-Segev OH, et al
    Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study.
    Ann Neurol. 2024 Jun 18. doi: 10.1002/ana.27008.
    >> Share

  30. KANAZAWA T, Sato W, Raveney BJE, Takewaki D, et al
    Pathogenic Potential of Eomesodermin-Expressing T-Helper Cells in Neurodegenerative Diseases.
    Ann Neurol. 2024;95:1093-1098.
    >> Share

    May 2024
  31. DICARLO M, Pignataro P, Zecca C, Dell'Abate MT, et al
    Irisin Levels in Cerebrospinal Fluid Correlate with Biomarkers and Clinical Dementia Scores in Alzheimer Disease.
    Ann Neurol. 2024 May 23. doi: 10.1002/ana.26946.
    >> Share

  32. CHEN XQ, Becker A, Albay R, Nguyen PD, et al
    gamma-Secretase Modulator BPN15606 Reduced Abeta42 and Abeta40 and Countered Alzheimer-Related Pathologies in a Mouse Model of Down Syndrome.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26958.
    >> Share

  33. HARRISON TM, Chadwick T, Pezzoli S, Lee J, et al
    Cognitive Trajectories and Alzheimer Disease Biomarkers: From Successful Cognitive Aging to Clinical Impairment.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26964.
    >> Share

  34. LAN G, Chen X, Yang J, Sun P, et al
    Microglial Reactivity Correlates with Presynaptic Loss Independent of beta-Amyloid and Tau.
    Ann Neurol. 2024;95:917-928.
    >> Share

    April 2024
  35. GARCIA-CORDERO I, Anastassiadis C, Khoja A, Morales-Rivero A, et al
    Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy.
    Ann Neurol. 2024 Apr 5. doi: 10.1002/ana.26930.
    >> Share

  36. SAKOWSKI SA, Koubek EJ, Chen KS, Goutman SA, et al
    Role of the Exposome in Neurodegenerative Disease: Recent Insights and Future Directions.
    Ann Neurol. 2024;95:635-652.
    >> Share

  37. ARVANITAKIS Z, Capuano AW, Tong H, Mehta RI, et al
    Associations of Serum Insulin and Related Measures With Neuropathology and Cognition in Older Persons With and Without Diabetes.
    Ann Neurol. 2024;95:665-676.
    >> Share

    March 2024

  38. Retraction: 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of alzheimer disease.
    Ann Neurol. 2024 Mar 28. doi: 10.1002/ana.26938.
    >> Share

  39. PALPATZIS E, Akinci M, Aguilar-Dominguez P, Garcia-Prat M, et al
    Lifetime Stressful Events Associated with Alzheimer's Pathologies, Neuroinflammation and Brain Structure in a Risk Enriched Cohort.
    Ann Neurol. 2024 Mar 11. doi: 10.1002/ana.26881.
    >> Share

  40. LACHNER C, Craver EC, Babulal GM, Lucas JA, et al
    Disparate Dementia Risk Factors Are Associated with Cognitive Impairment and Rates of Decline in African Americans.
    Ann Neurol. 2024;95:518-529.
    >> Share

  41. PAPP KV, Jutten RJ, Soberanes D, Weizenbaum E, et al
    Early Detection of Amyloid-Related Changes in Memory among Cognitively Unimpaired Older Adults with Daily Digital Testing.
    Ann Neurol. 2024;95:507-517.
    >> Share

    February 2024
  42. VAN EGROO M, van Someren EJW, Grinberg LT, Bennett DA, et al
    Associations of 24-Hour Rest-Activity Rhythm Fragmentation, Cognitive Decline, and Postmortem Locus Coeruleus Hypopigmentation in Alzheimer's Disease.
    Ann Neurol. 2024 Feb 26. doi: 10.1002/ana.26880.
    >> Share

  43. LI Y, Yen D, Hendrix RD, Gordon BA, et al
    Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26891.
    >> Share

  44. PHAN TX, Baratono S, Drew W, Tetreault AM, et al
    Increased Cortical Thickness in Alzheimer's Disease.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26894.
    >> Share

  45. SALTIEL N, Tripodis Y, Menzin T, Olaniyan A, et al
    Relative Contributions of Mixed Pathologies to Cognitive and Functional Symptoms in Brain Donors Exposed to Repetitive Head Impacts.
    Ann Neurol. 2024;95:314-324.
    >> Share

  46. KUCHENBECKER LA, Tipton PW, Martens Y, Brier MR, et al
    Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia.
    Ann Neurol. 2024;95:299-313.
    >> Share

  47. CHEN X, Toueg TN, Harrison TM, Baker SL, et al
    Regional Tau Deposition Reflects Different Pathways of Subsequent Neurodegeneration and Memory Decline in Cognitively Normal Older Adults.
    Ann Neurol. 2024;95:249-259.
    >> Share

    January 2024
  48. VANCE JM, Farrer LA, Huang Y, Cruchaga C, et al
    Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease.
    Ann Neurol. 2024 Jan 5. doi: 10.1002/ana.26864.
    >> Share

    December 2023
  49. BONOMI S, Lu R, Schindler SE, Bui Q, et al
    Relationships of Cognitive Measures with Cerebrospinal Fluid but not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals.
    Ann Neurol. 2023 Dec 1. doi: 10.1002/ana.26838.
    >> Share

    October 2023
  50. ZHENG L, Rubinski A, Dennecke J, Luan Y, et al
    Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer's Disease.
    Ann Neurol. 2023 Oct 14. doi: 10.1002/ana.26818.
    >> Share

  51. GRILL JD, Flournoy C, Dhadda S, Ernstrom K, et al
    Eligibility rates among racially and ethnically diverse US participants in Phase 2 and Phase 3 placebo-controlled, double-blind, randomized trials of lecanemab and elenbecestat in early Alzheimer's disease.
    Ann Neurol. 2023 Oct 13. doi: 10.1002/ana.26819.
    >> Share

  52. DARK HE, Paterson C, Daya GN, Peng Z, et al
    Proteomic indicators of health predict Alzheimer's disease biomarker levels and dementia risk.
    Ann Neurol. 2023 Oct 6. doi: 10.1002/ana.26817.
    >> Share

  53. SHAW LM, Galasko D
    Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and AD.
    Ann Neurol. 2023;94:618-619.
    >> Share

  54. SOLDAN A, Oh S, Ryu T, Pettigrew C, et al
    NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment.
    Ann Neurol. 2023;94:620-631.
    >> Share

    September 2023
  55. HIRATA K, Matsuoka K, Tagai K, Endo H, et al
    Altered brain energy metabolism related to astrocytes in Alzheimer's disease.
    Ann Neurol. 2023 Sep 13. doi: 10.1002/ana.26797.
    >> Share

    August 2023
  56. MINOGUE G, Kawles A, Zouridakis A, Keszycki R, et al
    Distinct Patterns of Hippocampal Pathology in Alzheimer's Disease with TDP-43.
    Ann Neurol. 2023 Aug 18. doi: 10.1002/ana.26762.
    >> Share

  57. KOSIK KS
    Search Strategies for Alzheimer Protector Genes.
    Ann Neurol. 2023 Aug 13. doi: 10.1002/ana.26764.
    >> Share

  58. YU L, Petyuk VA, Lopes KP, Tasaki S, et al
    Associations of VGF with Neuropathologies and Cognitive Health in Older Adults.
    Ann Neurol. 2023;94:232-244.
    >> Share

  59. CHEN XQ, Sawa M, Becker A, Karachentsev D, et al
    Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a gamma-Secretase Modulator.
    Ann Neurol. 2023;94:245-258.
    >> Share

    July 2023
  60. KUHLENBAUMER G, Jensen-Kondering U, Margraf NG
    Decreased Cerebrospinal Fluid Amyloid Beta 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
    Ann Neurol. 2023;94:205.
    >> Share

  61. LUCEY BP, Liu H, Toedebusch CD, Freund D, et al
    Suvorexant Acutely Decreases Tau Phosphorylation and Abeta in the Human CNS.
    Ann Neurol. 2023;94:27-40.
    >> Share

    June 2023
  62. LUCEY BP, Bateman RJ
    Reply to Suvorexant for preventing Alzheimer's disease.
    Ann Neurol. 2023 Jun 28. doi: 10.1002/ana.26728.
    >> Share

  63. KAWADA T
    Suvorexant for preventing Alzheimer's disease.
    Ann Neurol. 2023 Jun 27. doi: 10.1002/ana.26733.
    >> Share

  64. DE KORT AM, Kuiperij HB, Marques TM, Jakel L, et al
    Decreased Cerebrospinal Fluid Amyloid beta 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
    Ann Neurol. 2023;93:1173-1186.
    >> Share

    May 2023
  65. NELSON PT, Schneider JA, Jicha GA, Duong MT, et al
    When Alzheimer's is LATE: Why does it matter?
    Ann Neurol. 2023 May 28. doi: 10.1002/ana.26711.
    >> Share

  66. HOOSHMAND B, Appold F, Fissler P, Perneczky R, et al
    Markers of vitamin B12 status in relation to cerebrospinal fluid biomarkers of Alzheimer's disease and cognitive performance.
    Ann Neurol. 2023 May 12. doi: 10.1002/ana.26673.
    >> Share

  67. ANDRE C, Champetier P, Rehel S, Kuhn E, et al
    Rapid Eye Movement Sleep, Neurodegeneration, and Amyloid Deposition in Aging.
    Ann Neurol. 2023;93:979-990.
    >> Share

    April 2023
  68. NEDELEC T, Couvy-Duchesne B, Darves-Bornoz A, Couronne R, et al
    A comparison between early presentation of dementia with Lewy Bodies, Alzheimer's disease and Parkinson's disease: evidence from routine primary care and UK Biobank data.
    Ann Neurol. 2023 Apr 25. doi: 10.1002/ana.26670.
    >> Share

  69. SHAHID M, Rawls A, Ramirez V, Ryman S, et al
    Illusory Responses across the Lewy Body Disease Spectrum.
    Ann Neurol. 2023;93:702-714.
    >> Share

    March 2023
  70. MUSIEK ES, McDade E, Holtzman DM
    Lecanamab ushers in a new era of anti-amyloid therapy for Alzheimer's Disease.
    Ann Neurol. 2023 Mar 15. doi: 10.1002/ana.26643.
    >> Share

  71. PYUN JM, Park YH, Wang J, Bice PJ, et al
    Aberrant GAP43 gene expression is Alzheimer's disease pathology-specific.
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26637.
    >> Share

  72. LAN G, Guo T
    Reply to: "Aberrant GAP43 gene expression is Alzheimer's disease pathology-specific".
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26639.
    >> Share

  73. TROPEA TF, Albuja I, Cousins KAQ, Irwin DJ, et al
    Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia.
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26635.
    >> Share

  74. YOUNCE JR, Martin WRW, Perlmutter JS
    Reply to "Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia".
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26630.
    >> Share

    February 2023
  75. HORIE K, Li Y, Barthelemy NR, Gordon BA, et al
    Change in cerebrospinal fluid tau microtubule binding region detects symptom onset, cognitive decline, tangles, and atrophy in Dominantly Inherited Alzheimer's Disease.
    Ann Neurol. 2023 Feb 26. doi: 10.1002/ana.26620.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016